Cystic fibrosis heterozygotes do not have increased platelet activation

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Cystic fibrosis heterozygotes do not have increased platelet activation. / Tarnow, Inge; Michelson, Alan D.; Frelinger III, Andrew L.; Linden, Matthew D.; Li, Youfu; Fox, Marsha L.; Barnard, Marc R.; O'Sullivan, Brian P.

In: Thrombosis Research, Vol. 121, No. 2, 2007, p. 159-162.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Tarnow, I, Michelson, AD, Frelinger III, AL, Linden, MD, Li, Y, Fox, ML, Barnard, MR & O'Sullivan, BP 2007, 'Cystic fibrosis heterozygotes do not have increased platelet activation', Thrombosis Research, vol. 121, no. 2, pp. 159-162. https://doi.org/10.1016/j.thromres.2007.04.004

APA

Tarnow, I., Michelson, A. D., Frelinger III, A. L., Linden, M. D., Li, Y., Fox, M. L., Barnard, M. R., & O'Sullivan, B. P. (2007). Cystic fibrosis heterozygotes do not have increased platelet activation. Thrombosis Research, 121(2), 159-162. https://doi.org/10.1016/j.thromres.2007.04.004

Vancouver

Tarnow I, Michelson AD, Frelinger III AL, Linden MD, Li Y, Fox ML et al. Cystic fibrosis heterozygotes do not have increased platelet activation. Thrombosis Research. 2007;121(2):159-162. https://doi.org/10.1016/j.thromres.2007.04.004

Author

Tarnow, Inge ; Michelson, Alan D. ; Frelinger III, Andrew L. ; Linden, Matthew D. ; Li, Youfu ; Fox, Marsha L. ; Barnard, Marc R. ; O'Sullivan, Brian P. / Cystic fibrosis heterozygotes do not have increased platelet activation. In: Thrombosis Research. 2007 ; Vol. 121, No. 2. pp. 159-162.

Bibtex

@article{722b06e0a1c311ddb6ae000ea68e967b,
title = "Cystic fibrosis heterozygotes do not have increased platelet activation",
abstract = "Introduction: We have previously demonstrated platelet hyperreactivity in cystic fibrosis (CF) patients. Carriers of one CF m utation (heterozygotes) have been shown to have abnormalities related to the presence of only one-half the normal amount of CF transmembrane conductance regulator protein. Platelet hyperreactivity in CF heterozygotes would be an important cardiovascular risk factor, since approximately 1 in 25 Caucasians is a CF carrier.Materials and methods: We used highly sensitive assays of platelet activation to assess the difference between 16 CF heterozygotes and 16 age- and sex-matched healthy controls without CF mutations.Results: We found no difference in platelet activation between CF heterozygotes and controls.Conclusions: The 50% reduction in the CF transmembrane conductance regulator protein in heterozygotes is insufficient to cause platelet activation.",
keywords = "Former LIFE faculty, Platelets, Cystic fibrosis, Flow cytometry, Cystic fibrosis carriers, Platelet function",
author = "Inge Tarnow and Michelson, {Alan D.} and {Frelinger III}, {Andrew L.} and Linden, {Matthew D.} and Youfu Li and Fox, {Marsha L.} and Barnard, {Marc R.} and O'Sullivan, {Brian P.}",
year = "2007",
doi = "10.1016/j.thromres.2007.04.004",
language = "English",
volume = "121",
pages = "159--162",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Pergamon Press",
number = "2",

}

RIS

TY - JOUR

T1 - Cystic fibrosis heterozygotes do not have increased platelet activation

AU - Tarnow, Inge

AU - Michelson, Alan D.

AU - Frelinger III, Andrew L.

AU - Linden, Matthew D.

AU - Li, Youfu

AU - Fox, Marsha L.

AU - Barnard, Marc R.

AU - O'Sullivan, Brian P.

PY - 2007

Y1 - 2007

N2 - Introduction: We have previously demonstrated platelet hyperreactivity in cystic fibrosis (CF) patients. Carriers of one CF m utation (heterozygotes) have been shown to have abnormalities related to the presence of only one-half the normal amount of CF transmembrane conductance regulator protein. Platelet hyperreactivity in CF heterozygotes would be an important cardiovascular risk factor, since approximately 1 in 25 Caucasians is a CF carrier.Materials and methods: We used highly sensitive assays of platelet activation to assess the difference between 16 CF heterozygotes and 16 age- and sex-matched healthy controls without CF mutations.Results: We found no difference in platelet activation between CF heterozygotes and controls.Conclusions: The 50% reduction in the CF transmembrane conductance regulator protein in heterozygotes is insufficient to cause platelet activation.

AB - Introduction: We have previously demonstrated platelet hyperreactivity in cystic fibrosis (CF) patients. Carriers of one CF m utation (heterozygotes) have been shown to have abnormalities related to the presence of only one-half the normal amount of CF transmembrane conductance regulator protein. Platelet hyperreactivity in CF heterozygotes would be an important cardiovascular risk factor, since approximately 1 in 25 Caucasians is a CF carrier.Materials and methods: We used highly sensitive assays of platelet activation to assess the difference between 16 CF heterozygotes and 16 age- and sex-matched healthy controls without CF mutations.Results: We found no difference in platelet activation between CF heterozygotes and controls.Conclusions: The 50% reduction in the CF transmembrane conductance regulator protein in heterozygotes is insufficient to cause platelet activation.

KW - Former LIFE faculty

KW - Platelets

KW - Cystic fibrosis

KW - Flow cytometry

KW - Cystic fibrosis carriers

KW - Platelet function

U2 - 10.1016/j.thromres.2007.04.004

DO - 10.1016/j.thromres.2007.04.004

M3 - Journal article

C2 - 17532368

VL - 121

SP - 159

EP - 162

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 2

ER -

ID: 8094892